Click here for the CME evaluation / post-test

Activity Index
Click on the titles below to view the presentations.

Thursday, November 8, 2007

Session I: Myelodysplasia
Chair: John M. Bennett, MD and Alan F. List, MD

Classification and morphology of myelodysplastic diseases
Attilio Orazi, MD

Event-associated (secondary) myelodysplasia
John M. Bennett, MD

Update on lenalidomide and other drugs
Alan F. List, MD

Arsenic in MDS
Gail J. Roboz, MD

What transplant and when for patients with MDS
H. Joachim Deeg, MD

Keynote address: Lessons from kinase inhibitors
Charles L. Sawyers, MD

Session II: Myelofibrosis
Chairs: Giovanni Barosi, MD and Ayalew Tefferi, MD

The role of JAK2V617F mutation in the pathogenesis and progression of myelofibrosis with myeloid metaplasia
Giovanni Barosi, MD

NF-E2 in the pathophysiology of MPDs
Heike L. Pahl, PhD

Myelofibrosis: A stem cell disease
Ronald Hoffman, MD

Clinical and therapeutic implications of megakaryocyte-stem cell niche deregulation in primary myelofibrosis
Marie-Caroline Le Bousse-Kerdilès, PhD

Transplantation in myelofibrosis
Francisco Cervantes, MD

Treatment of myelofibrosis diseases: Current challenges and future prospects
Ruben A. Mesa, MD

Friday, November 9, 2007

Session III: Polycythemia Vera and Essential Thrombocytopenia, Myeloproliferative Diseases
Chairs: Nick C.P. Cross, MA, PhD, FRCPath and Jerry L. Spivak, MD, FACP

Genetics of myeloproliferative disorders with emphasis on ET
Radek Skoda, MD

Erythrocytosis: Congenital and nonclonal
Josef T. Prchal, MD

JAK2V617F allele burden: Clinical correlates and genetic modifiers
Alison R. Moliterno, MD

Risk factors for survival, leukemic transformation, and thrombosis in essential thrombocythemia and polycythemia vera: Mayo Clinic experience
Ayalew Tefferi, MD

The role of bone marrow histopathology in the diagnosis of essential thrombocythemia
Peter Campbell, MD

“Modern” management of polycythemia vera
Richard T. Silver, MD, FACP

Session IV: Polycythemia Vera and Essential Thrombocytopenia, Myeloproliferative Diseases, continued
Chair: Ronald Hoffman, MD and Richard T. Silver, MD, FACP

Molecular drug targets in myeloproliferative disorders
D. Gary Gilliland, MD, PhD

Pathogenesis and management of the MPDs
Anthony R. Green, PhD, FRCP, FRCPath

Leukocytosis and the risk of thrombosis in ET & PV
Tiziano Barbui, MD

BCR-ABL negative myeloproliferative diseases
Nick C.P. Cross, MA, PhD, FRCPath

The fallacy of the partial cytogenetic response
Vesna Najfeld, PhD

How can one mutation explain 3 different MPDs?
Chloe James, MD

Selected Oral Abstract Presentations
Chair: Jerry L. Spivak, MD, FACP

Committee: Nick C.P. Cross, MA, PhD, FRCPath, Ruben A. Mesa, MD, and
Jerry L Spivak, MD, FACP

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
E Antonioli, et al.

Characterization of differentially expressed microRNAs in granulocytes from primary myelofibrosis
P Guglielmelli, et al.

JAK2 Exon 12 Mutations in patients diagnosed with Polycythemia Vera or Idiopathic Erythrocytosis: Characteristics at presentation and during follow-up
L Scott, et al.

Saturday, November 10, 2007

Session V: Chronic Myeloid Leukemia (CML)
Chairs: John Goldman, MD and Rudiger Hehlmann, MD, PhD

Inhibiting BCR-ABL signal transduction: BCR-ABL formation, mechanisms of action of the different TK inhibitors, possible downstream targets for therapy
Giuseppe Saglio, MD

Imatinib updated: Clinical data, dosage, toxicity, stopping, pregnancy and case history
Hagop Kantarjian, MD

Monitoring response to therapy: Cytogenetics and PCR, defining response and failure and case history
John Goldman, MD

Imatinib resistance: Classifications and mechanisms of resistance
Michael Deininger, MD, PhD

Second and third generation tyrosine kinase inhibitors: Initial clinical results and toxicity, and case history
Jorge Cortes, MD

Prospective clinical trials: Questions to be addressed in 2007 (useable endpoints, statistical considerations, survey of German and international phase III studies)
Rudiger Hehlmann, MD, PhD

Click here for the CME evaluation / post-test